Literature DB >> 33864791

Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Wanjian Tang1, Jinghua Ge1, William C Unrath1, Rohini Desetty1, Christopher M Yengo2.   

Abstract

Cardiac muscle contraction is driven by the molecular motor myosin, which uses the energy from ATP hydrolysis to generate a power stroke when interacting with actin filaments, although it is unclear how this mechanism is impaired by mutations in myosin that can lead to heart failure. We have applied a fluorescence resonance energy transfer (FRET) strategy to investigate structural changes in the lever arm domain of human β-cardiac myosin subfragment 1 (M2β-S1). We exchanged the human ventricular regulatory light chain labeled at a single cysteine (V105C) with Alexa 488 onto M2β-S1, which served as a donor for Cy3ATP bound to the active site. We monitored the FRET signal during the actin-activated product release steps using transient kinetic measurements. We propose that the fast phase measured with our FRET probes represents the macroscopic rate constant associated with actin-activated rotation of the lever arm during the power stroke in M2β-S1. Our results demonstrated M2β-S1 has a slower actin-activated power stroke compared with fast skeletal muscle myosin and myosin V. Measurements at different temperatures comparing the rate constants of the actin-activated power stroke and phosphate release are consistent with a model in which the power stroke occurs before phosphate release and the two steps are tightly coupled. We suggest that the actin-activated power stroke is highly reversible but followed by a highly irreversible phosphate release step in the absence of load and free phosphate. We demonstrated that hypertrophic cardiomyopathy (R723G)- and dilated cardiomyopathy (F764L)-associated mutations both reduced actin activation of the power stroke in M2β-S1. We also demonstrate that both mutations alter in vitro actin gliding in the presence and absence of load. Thus, examining the structural kinetics of the power stroke in M2β-S1 has revealed critical mutation-associated defects in the myosin ATPase pathway, suggesting these measurements will be extremely important for establishing structure-based mechanisms of contractile dysfunction.
Copyright © 2021 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33864791      PMCID: PMC8390809          DOI: 10.1016/j.bpj.2021.04.007

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   3.699


  74 in total

1.  The size and the speed of the working stroke of muscle myosin and its dependence on the force.

Authors:  Gabriella Piazzesi; Leonardo Lucii; Vincenzo Lombardi
Journal:  J Physiol       Date:  2002-11-15       Impact factor: 5.182

2.  Kinetics and thermodynamics of the rate-limiting conformational change in the actomyosin V mechanochemical cycle.

Authors:  Donald J Jacobs; Darshan Trivedi; Charles David; Christopher M Yengo
Journal:  J Mol Biol       Date:  2011-02-17       Impact factor: 5.469

3.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

4.  A Perspective on the Role of Myosins as Mechanosensors.

Authors:  Michael J Greenberg; Göker Arpağ; Erkan Tüzel; E Michael Ostap
Journal:  Biophys J       Date:  2016-06-21       Impact factor: 4.033

5.  Mechanism of adenosine triphosphate hydrolysis by actomyosin.

Authors:  R W Lymn; E W Taylor
Journal:  Biochemistry       Date:  1971-12-07       Impact factor: 3.162

6.  Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil.

Authors:  Wanjian Tang; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  J Biol Chem       Date:  2019-10-02       Impact factor: 5.157

7.  Purification of muscle actin.

Authors:  J D Pardee; J A Spudich
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

8.  Models of calcium activation account for differences between skeletal and cardiac force redevelopment kinetics.

Authors:  W O Hancock; L L Huntsman; A M Gordon
Journal:  J Muscle Res Cell Motil       Date:  1997-12       Impact factor: 3.352

9.  Elevated rates of force development and MgATP binding in F764L and S532P myosin mutations causing dilated cardiomyopathy.

Authors:  Bradley M Palmer; Joachim P Schmitt; Christine E Seidman; J G Seidman; Yuan Wang; Stephen P Bell; Martin M Lewinter; David W Maughan
Journal:  J Mol Cell Cardiol       Date:  2013-01-08       Impact factor: 5.000

10.  Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.

Authors:  Zoltan Ujfalusi; Carlos D Vera; Srbolujub M Mijailovich; Marina Svicevic; Elizabeth Choe Yu; Masataka Kawana; Kathleen M Ruppel; James A Spudich; Michael A Geeves; Leslie A Leinwand
Journal:  J Biol Chem       Date:  2018-04-17       Impact factor: 5.157

View more
  1 in total

Review 1.  Recent insights into the relative timing of myosin's powerstroke and release of phosphate.

Authors:  Edward P Debold
Journal:  Cytoskeleton (Hoboken)       Date:  2022-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.